Jazz Pharmaceuticals PLC (JAZZ) Director Sells $1,257,570.00 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Patrick G. Enright sold 9,000 shares of the firm’s stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $139.73, for a total value of $1,257,570.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Shares of Jazz Pharmaceuticals PLC (NASDAQ JAZZ) opened at $135.53 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.10 and a quick ratio of 2.94. Jazz Pharmaceuticals PLC has a 1-year low of $104.82 and a 1-year high of $163.75. The company has a market capitalization of $8,123.29, a P/E ratio of 17.00, a price-to-earnings-growth ratio of 0.87 and a beta of 0.98.

Several analysts recently commented on the company. J P Morgan Chase & Co reaffirmed a “buy” rating and set a $190.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, September 18th. Royal Bank of Canada reaffirmed a “buy” rating and set a $210.00 target price on shares of Jazz Pharmaceuticals in a report on Friday, September 15th. BMO Capital Markets reaffirmed a “buy” rating and set a $196.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, September 20th. Morgan Stanley assumed coverage on Jazz Pharmaceuticals in a report on Thursday, October 5th. They set an “equal weight” rating and a $155.00 target price on the stock. Finally, Goldman Sachs Group assumed coverage on Jazz Pharmaceuticals in a report on Thursday, September 28th. They set a “neutral” rating and a $165.00 target price on the stock. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and nineteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $181.28.

Institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC lifted its position in shares of Jazz Pharmaceuticals by 11.4% in the second quarter. FMR LLC now owns 8,290,410 shares of the specialty pharmaceutical company’s stock valued at $1,289,159,000 after acquiring an additional 849,348 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Jazz Pharmaceuticals by 3.4% in the second quarter. Vanguard Group Inc. now owns 4,677,223 shares of the specialty pharmaceutical company’s stock valued at $727,308,000 after acquiring an additional 153,908 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Jazz Pharmaceuticals by 7.7% in the third quarter. Bank of New York Mellon Corp now owns 1,486,426 shares of the specialty pharmaceutical company’s stock valued at $217,390,000 after acquiring an additional 105,838 shares in the last quarter. Westfield Capital Management Co. LP lifted its position in shares of Jazz Pharmaceuticals by 8.7% in the third quarter. Westfield Capital Management Co. LP now owns 1,438,481 shares of the specialty pharmaceutical company’s stock valued at $210,378,000 after acquiring an additional 115,217 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Jazz Pharmaceuticals by 41.2% in the second quarter. JPMorgan Chase & Co. now owns 1,405,408 shares of the specialty pharmaceutical company’s stock valued at $218,540,000 after acquiring an additional 410,031 shares in the last quarter. 91.30% of the stock is currently owned by institutional investors.

WARNING: “Jazz Pharmaceuticals PLC (JAZZ) Director Sells $1,257,570.00 in Stock” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://stocknewstimes.com/2017/12/16/jazz-pharmaceuticals-plc-jazz-director-sells-1257570-00-in-stock.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply